In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

with patients losing roughly a quarter of their body weight in one year. "You have GLP-1 receptor agonist, you have GIP receptor agonist, but then we're adding the pharmacology of glucagon as well ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.

Pancreatic neuroendocrine tumours and liver cancer can hijack the body’s metabolic processes, using glucagon to increase glucose production and fuel their growth. In advanced liver cancer ...

"We've long known that the brain can directly signal the pancreas to release hormones quickly, but our work shows it can also indirectly boost glucagon production via immune cells, making the body ...

Ozempic works by mimicking the hormone GLP-1, which suppresses hunger and regulates blood sugar levels. All semaglutide ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

"We've long known that the brain can directly signal the pancreas to release hormones quickly, but our work shows it can also indirectly boost glucagon production via immune cells, making the body ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...